Problemi speciali
La malattia drepanocitica in Pronto Soccorso
Sickle cell disease at tha Emergency Unit
M. Casale, S. Perrotta, G. Russo, L. Sainati, R. Colombatti, G.L. Forni
Dicembre 2019 - pagg. 639 -644
Abstract
Sickle cell disease is the most common genetic disorder observed at emergency units
worldwide with more and more children being diagnosed with severe acute events. Emergency
caregivers need to be aware of potentially life-threatening complications because
fast and clear protocols were shown to guarantee the most appropriate approach to children
with acute crises related to sickle cell disease. The Italian Society of Thalassemias and
Hemoglobinopathies (SITE) coordinated a multidisciplinary group to design an interactive
algorithm for the management of the most common and serious complications in sickle cell
disease. Topics of interest are accessed by clicking on different windows with handiness
and reliability. This evidence-based and easy to handle algorithm helps in the decisionmaking
processes and therapeutic management of severe acute events in children with sickle
cell disease and aims to a rapid and aggressive treatment of life-threatening crises and
the decrease in mortality and long-term disabilities in sickle cell children
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Rees DC, Williams TN, Gladwin MT. Sickle-
cell disease. Lancet 2010;376:2018-31.
2. WHO Report A59/9 on sickle cell anemia.
2006.
3. UN Resolution A/63/L. 63. Recognition of
sickle-cell anaemia as a public health problem.
2008.
4. Piel FB, Hay SI, Gupta S, Weatherall DJ,
Williams TN. Global burden of sickle cell
anaemia in children under five, 2010-2050:
modelling based on demographics, excess
mortality, and interventions. PLoS Med
2013;10:e1001484.
5. De Franceschi L, Lux C, Piel FB, et al. Access
to emergency departments for acute
events and identification of sickle cell disease
in refugees. Blood 2019;133:2100-2103.
6. Russo G, De Franceschi L, Colombatti R,
et al. Current challenges in the management
of patients with sickle cell disease - A report
of the Italian experience. Orphanet J Rare
Dis. 2019;14:120.
7. Casale M, Russo G, Sainati L, et al. La gestione
del rischio infettivo nei bambini asplenici:
Raccomandazioni dal network italiano
asplenia. Quaderni acp 2019;26(4):158-61.
8. Colombatti R, Palazzi G, Masera N, et al.
Italian Multicenter Study of Hydroxyurea in
Sickle Cell Anemia Investigators. Hydroxyurea
prescription, availability and use for children
with sickle cell disease in Italy: Results
of a National Multicenter survey. Pediatr
Blood Cancer 2018;65(2).
9. Colombatti R, Perrotta S, Samperi P, Casale
M, Masera N, Palazzi G, et al. Organizing
national responses for rare blood disorders:
the Italian experience with sickle cell disease
in childhood. Orphanet J Rare Dis 2013;8:
169.
10. Forni GL, Finco G, Graziadei G, et al. Development
of interactive algorithm for clinical
management of acute events related to
sickle cell disease in Emergency Department.
Orphanet J Rare Dis 2014;9:91.
11. Casale M, Filosa A, Ragozzino A, et al.
Long-term improvement in cardiac magnetic
resonance in β thalassemia major patients
treated with deferasirox extends to patients
with abnormal baseline cardiac function. Am
J Hematol 2019;94(3):312-8.
12. Casale M, Citarella S, Filosa A, et al. Endocrine
function and bone disease during
long-term chelation therapy with deferasirox
in patients with β-thalassemia major. Am J
Hematol 2014;89(12):1102-6.
13. Casale M, Picariello S, Corvino F, et al.
Life-threatening drug-induced liver injury in
a patient with β-thalassemia major and severe
iron overload on polypharmacy. Hemoglobin
2018;42(3):213-6.
14. Casale M, Marsella M, Ammirabile M, et
al. Predicting factors for liver iron overload at
the first magnetic resonance in children with
thalassaemia major. Blood Transfus 2019;17
(3):165-170.
15. Casale M, Meloni A, Filosa A, et al. Multiparametric
cardiac magnetic resonance survey
in children with thalassemia major: a
multicenter study. Circ Cardiovasc Imaging
2015;8(8):e003230.
16. Casale M, Cozzolino F, Scianguetta S, et
al. Hb Vanvitelli: a new unstable α-globin
chain variant causes undiagnosed chronic
haemolytic anaemia when co-inherited with
deletion - α(3.7). Clin Biochem 2019;S0009-
9120(19):30851-3.
17. Ladogana S, Maruzzi M, Samperi P, et al.
Second-line therapy in paediatric warm autoimmune
haemolytic anaemia. Guidelines
from the Associazione Italiana Onco-Ematologia
Pediatrica (AIEOP). Blood Transfus
2018;16(4):352-7.
18. Franchini M, Forni GL, Marano G, et al.
Red blood cell alloimmunisation in transfusion-
dependent thalassaemia: a systematic
review. Blood Transfus 2019;17(1):4-15.
19. Mancusi S, La Manna A, Bellini G, et al.
HNF-1β mutation affects PKD2 and SOCS3
expression causing renal cysts and diabetes
in MODY5 kindred. J Nephrol 2013;26(1):
207-12.
20. Casale M, Perrotta S. Splenectomy for hereditary
spherocytosis: complete, partial or
not at all? Expert Rev Hematol 2011;4(6):627-
35.
21. Fermo E, Vercellati C, Marcello AP, et al.
Clinical and molecular spectrum of glucose-
6-phosphate isomerase deficiency. Report of
12 New Cases. Front Physio. 2019;10:467.
22. Novelli EM, Gladwin MT. Crises in sickle
cell disease. Chest 2016; 149(4):1082-93.
23. Moussavou A, Vierin Y, Eloundou-Orima
C, Mboussou M, Keita M. Sickle cell disease
pain management following the World
Health Organization’s protocol. Arch Pediatr
2004;11:1041-5.
24. Inusa B, Casale M, Booth C, Lucas S. Subarachnoid
haemorrhage and cerebral vasculopathy
in a child with sickle cell anaemia.
BMJ Case Rep 2014;2014.
25. Brousse V, Arnaud C, Lesprit E, et al.
Evaluation of outcomes and quality of care in
children with sickle cell disease diagnosed
by newborn screening: a real-world nationwide
study in France. J Clin Med 2019;8(10).
Corrispondenza: maddalena.casale@unicampania.it